Related Experiment Video

Updated: Aug 8, 2026

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice
15:43

Long Term Chronic Pseudomonas aeruginosa Airway Infection in Mice

Published on: March 18, 2014

DNA vaccines against chronic lung infections by Pseudomonas aeruginosa

J Staczek1, L B Gilleland, H C van der Heyde

  • 1Department of Microbiology and Immunology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932, USA. jstacz@lsuhsc.edu

FEMS Immunology and Medical Microbiology
|July 2, 2003
PubMed

Insights

Outer membrane protein F (OprF) vaccines protect against Pseudomonas aeruginosa infections. Surprisingly, cell-mediated immunity, not just antibodies, plays a crucial role in this protection, even in B-cell-deficient mice.

Area of Science:

  • Microbiology
  • Immunology
  • Vaccinology

Background:

  • Pseudomonas aeruginosa is a significant opportunistic pathogen.
  • Outer membrane protein F (OprF) is a target for P. aeruginosa vaccines.
  • Previous studies showed OprF-based vaccines reduce lesion severity in mouse models.

Purpose of the Study:

  • To investigate the role of antibody-mediated versus cell-mediated immunity in OprF-based vaccine protection.
  • To evaluate the efficacy of an OprF-based vaccine (F/I) in B-cell-deficient mice.

Main Methods:

  • Immunization of B-cell-deficient [B(-)] and B-cell-intact [B(+)] mice with an F/I vaccine or control vector.
  • Challenge with Pseudomonas aeruginosa and assessment of pulmonary lesion severity.
  • Analysis of immune cell populations (CD3+ T-lymphocytes) and cytokine levels.

Main Results:

  • F/I vaccination reduced lesion severity in B(+) mice, confirming antibody-mediated protection.
  • Surprisingly, both F/I- and vector-immunized B(-) mice showed similar protection levels, comparable to F/I-immunized B(+) mice.
  • B(-) mice exhibited increased CD3+ T-lymphocyte populations, suggesting a role for cell-mediated immunity.

Conclusions:

  • Cell-mediated immunity plays a significant role in protection against P. aeruginosa infections.
  • OprF-based vaccines may induce protective cell-mediated immune responses in addition to antibody responses.
  • Further research into cell-mediated immunity mechanisms is warranted for vaccine development.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...